Technical Analysis for CYTO - Altamira Therapeutics Ltd.

Grade Last Price % Change Price Change
F 0.44 6.88% 0.03
CYTO closed up 6.88 percent on Wednesday, November 20, 2024, on 42 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down

Date Alert Name Type % Chg
Bullish Engulfing Bullish 0.00%
Calm After Storm Range Contraction 0.00%
NR7 Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Oversold Stochastic Weakness 0.00%
New 52 Week Closing Low Bearish 6.88%
Calm After Storm Range Contraction 6.88%
Wide Bands Range Expansion 6.88%
Lower Bollinger Band Touch Weakness 6.88%
Oversold Stochastic Weakness 6.88%

   Recent Intraday Alerts

Alert Time
Possible NR7 about 18 hours ago
Possible Inside Day about 18 hours ago
Up 5% about 22 hours ago
Up 3% about 22 hours ago
Up 2% about 22 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Altamira Therapeutics Ltd. Description

Altamira Therapeutics is a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders. The Company is focused on the development of intranasal betahistine for the treatment of vertigo (AM-125, in Phase 2) and for the prevention of antipsychotic-induced weight gain and somnolence (AM-201, post Phase 1b). Through its affiliate Altamira Medica, the Company is developing a nasal spray for protection against airborne pathogens and allergens (AM-301). In addition, Auris Medical has two Phase 3 programs under development: Sonsuvi® (AM-111) for acute inner ear hearing loss and Keyzilen® (AM-101) for acute inner ear tinnitus. The Company was founded in 2003 and is headquartered in Hamilton, Bermuda with its main operations in Basel, Switzerland. The shares of Auris Medical Holding Ltd. trade on the NASDAQ Capital Market under the symbol 'EARS.'


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Allergy Nervous System Otology

Is CYTO a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 17.2
52 Week Low 0.4
Average Volume 85,980
200-Day Moving Average 1.24
50-Day Moving Average 0.58
20-Day Moving Average 0.48
10-Day Moving Average 0.45
Average True Range 0.06
RSI (14) 36.71
ADX 36.0
+DI 16.21
-DI 20.15
Chandelier Exit (Long, 3 ATRs) 0.45
Chandelier Exit (Short, 3 ATRs) 0.57
Upper Bollinger Bands 0.54
Lower Bollinger Band 0.41
Percent B (%b) 0.23
BandWidth 28.52
MACD Line -0.05
MACD Signal Line -0.05
MACD Histogram 0.0019
Fundamentals Value
Market Cap 692.9 Thousand
Num Shares 1.58 Million
EPS -453.06
Price-to-Earnings (P/E) Ratio 0.00
Price-to-Sales 25.01
Price-to-Book 0.35
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.49
Resistance 3 (R3) 0.49 0.47 0.48
Resistance 2 (R2) 0.47 0.45 0.47 0.48
Resistance 1 (R1) 0.45 0.44 0.46 0.46 0.48
Pivot Point 0.43 0.43 0.44 0.43 0.43
Support 1 (S1) 0.42 0.42 0.43 0.42 0.40
Support 2 (S2) 0.40 0.41 0.40 0.40
Support 3 (S3) 0.39 0.40 0.40
Support 4 (S4) 0.39